RSV Vaccination Reduces Hospitalizations and Cardiovascular Complications in Elderly, Study Finds
A study analyzing data from more than 2.5 million people concluded that vaccination against respiratory syncytial virus (RSV) in elderly individuals was associated with a 75.6% reduction in hospitalizations from the disease.
In addition, vaccinated patients who required hospitalization after infection experienced 63.1% fewer severe cardiovascular problems, such as heart attack and stroke. The risk of worsening various comorbidities was also lower, including asthma, chronic obstructive pulmonary disease, diabetes, and kidney disease.
The study compared health information from approximately 520,000 people vaccinated with the Arexvy vaccine against 2 million unvaccinated people in the United States between August 2023 and May 2024, after statistical weighting.
During the nine months analyzed, the vaccinated group recorded not only fewer hospitalizations from the disease, but also 79.1% fewer severe hospitalizations and 66.8% fewer deaths.
The results were presented by pharmaceutical company GSK, manufacturer of the vaccine, at this year's edition of the Respiratory Syncytial Virus Foundation Conference.
According to GSK, the "real-world" data confirm the vaccine's efficacy, already demonstrated in clinical trials.
RSV is known primarily as the leading cause of bronchiolitis in infants, but it is also a virus that infects many elderly people with severity, explains cardiologist José Carlos Zanon, member of the Cardiogeriatrics Department of the Brazilian Society of Cardiology.
"As we age, our immune system undergoes a process of immunosenescence, and begins to have a reduced response to different types of infections, which predisposes people to more severe cases. Moreover, the percentage mortality rate among elderly people from RSV is higher than among children," Zanon explained.
Data from the Infogripe platform of the Oswaldo Cruz Foundation (Fiocruz) show that in the first half of this year RSV accounted for 38.1% of cases and 11.5% of deaths from severe acute respiratory syndrome with confirmed diagnosis for some viral infection. Elderly people are the second most affected group, after children up to 2 years of age.
Cases have been rising at this time of year, in keeping with the disease's seasonality. Considering only the month of June, severe cases caused by RSV account for more than 50% of those definitively caused by some respiratory virus.
According to the vice president of the Brazilian Society of Immunizations, Renato Kfouri, expanded diagnosis has enabled the health system to recognize the importance of RSV as a causative agent of severe respiratory disease among the elderly.
"Many studies show even longer hospitalization times than from the influenza virus, greater associated risk of death, especially in individuals who have chronic cardiovascular and pulmonary conditions," he adds.
Cardiologist José Carlos Zanon explains that in addition to affecting the respiratory tract, RSV causes an "inflammatory cascade" throughout the body and therefore can destabilize other diseases the patient already has, such as diabetes, or even cause heart problems and strokes.
In Brazil, vaccination against RSV is offered by the Unified Health System (SUS) only for pregnant women, with the aim of protecting newborns.
However, two vaccines have been approved for use in adults by the National Health Surveillance Agency (Anvisa) and are available in private clinics.
The Brazilian Society of Immunizations recommends that the vaccine be taken by all elderly people over 70 years of age, and by people between 60 and 70 years of age who have some risk factor.
The vaccine is also recommended for all immunocompromised adults.
